TABLE 1.
BL6 |
ICR |
|||||||
Arg− | Arg+ | Arg− | Arg+ | Gen | TRT | Gen × TRT | ||
Fluxes, μmol ⋅ kg−1 ⋅ h−1 | ||||||||
RaPhe2 | 330 ± 10 | 336 ± 16 | 326 ± 14 | 320 ± 17 | 0.52 | 0.99 | 0.71 | |
RaTyr2 | 298 ± 10 | 294 ± 14 | 276 ± 10 | 303 ± 12 | 0.62 | 0.43 | 0.29 | |
RcPhe→Tyr2 | 58 ± 5 | 55 ± 5 | 47 ± 3 | 68 ± 11 | 0.86 | 0.17 | 0.09 | |
Plasma concentrations, μmol/L | ||||||||
Citrulline | 124 ± 5 | 126 ± 11 | 170 ± 5 | 146 ± 7* | 0.001 | 0.23 | 0.16 | |
Arginine | 124 ± 8 | 165 ± 18 | 150 ± 16 | 147 ± 10 | 0.83 | 0.29 | 0.23 | |
Ornithine | 103 ± 11 | 109 ± 12 | 162 ± 4 | 131 ± 5* | 0.002 | 0.31 | 0.14 |
Values are means ± SEMs, n = 10. *Different from corresponding Arg−, P < 0.05. BL6, C57BL/6; Gen, genotype; ICR, Institute of Cancer Research; TRT, treatment.
RaPhe, RaTyr, and RcPhe→Tyr: rate of appearance of phenylalanine and tyrosine, and rate of conversion of phenylalanine into tyrosine.